All In Biotech

NDA 216109 · Hikma

Cefazolin Sodium

Cefazolin Sodium · Intravenous

Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Oct 7, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

207

37 Phase 3, 20 recruiting

FAERS reports

12,207

11,391 serious, 1,402 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 1, 2025.

Cefazolin for Injection is a cephalosporin antibacterial indicated for: Treatment of the following infections caused by susceptible isolates of the designated microorganisms in adult and pediatric patients 1 month of age and older for whom appropriate dosing with this formulation can be achieved: Respiratory tract infections ( 1.1 ) Urinary tract infections ( 1.2 ) Skin and skin structure infections ( 1.3 ) Biliary tract infections ( 1.4 ) Bone and joint infections ( 1.5 ) Genital infections ( 1.6 ) Septicemia ( 1.7 ) Endocarditis ( 1.8 ) Perioperative prophylaxis in adult patients ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and other antibacterial drugs, Cefazolin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ) 1.1 Respiratory Tract Infections Cefazolin for Injection is indicated for the treatment of respiratory tract infections due to Streptococcus pneumoniae, Klebsiella species, Hemophilus influenzae, Staphylococcus aureus (methicillin-susceptible), and Group A beta-hemolytic streptococciin adults and pediatric patients 1 month of age and older for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2.1 , 2.2 , 2.4 and 2.5) ]. Limitations of Use Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection is indicated for the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for Injection in the subsequent prevention of rheumatic fever are not available at present. 1.2 Urinary...

Mechanism: Cefazolin is an antibacterial drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 18, 2024 Supplement 3 · Efficacy LabelLetter
  • Oct 7, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
2 products under this application
  • CEFAZOLIN SODIUM · CEFAZOLIN SODIUM EQ 2GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription
  • CEFAZOLIN SODIUM · CEFAZOLIN SODIUM EQ 3GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cefazolin" as an intervention, any sponsor and status, largest first.

All 207 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension711
  • drug ineffective679
  • anaphylactic reaction659
  • anaphylactic shock622
  • rash600
  • pyrexia518
  • renal failure488
  • acute kidney injury442
  • off label use424
  • pain417
  • nausea379
  • urticaria361

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004222
2005210
2006255
2007157
2008238
2009224
2010233
2011507
2012462
2013268
2014304
2015373
2016540
2017510
2018700
2019831
2020855
2021805
2022954
20231,008
2024981
2025956
2026614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cefazolin Sodium* (Cefazolin Sodium)

2024 spending

$4.4M

Beneficiaries

20,069

82,069 claims

Per beneficiary

$218

$2.07 per unit

View as table
YearSpending
2020$4,102,820
2021$4,361,176
2022$4,768,566
2023$5,203,753
2024$4,371,640

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 629 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.